



## Clinical trial results:

**A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)**

### Summary

EudraCT number	2012-005417-38
Trial protocol	SK IT LV PT HU CZ ES LT BE GR DK DE PL FR
Global end of trial date	11 November 2015

### Results information

Result version number	v1
This version publication date	13 May 2016
First version publication date	13 May 2016

### Trial information

#### Trial identification

Sponsor protocol code	CRFB002G2301
-----------------------	--------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01840410
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111x,
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111x,

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 November 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	11 November 2015
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective was to demonstrate that an individualized regimen of intravitreal injection of 0.5 mg ranibizumab has superior efficacy compared to sham treatment in adult patients with visual impairment due to VEGF-driven CNV. It was assessed by the best-corrected visual acuity (BCVA) change from baseline to Month 2.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 September 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 10
Country: Number of subjects enrolled	Canada: 1
Country: Number of subjects enrolled	Czech Republic: 9
Country: Number of subjects enrolled	France: 3
Country: Number of subjects enrolled	Germany: 29
Country: Number of subjects enrolled	Hungary: 14
Country: Number of subjects enrolled	Italy: 21
Country: Number of subjects enrolled	Korea, Republic of: 10
Country: Number of subjects enrolled	Latvia: 7
Country: Number of subjects enrolled	Russian Federation: 12
Country: Number of subjects enrolled	Slovakia: 5
Country: Number of subjects enrolled	Spain: 11
Country: Number of subjects enrolled	Switzerland: 6
Country: Number of subjects enrolled	Turkey: 8
Country: Number of subjects enrolled	Denmark: 3
Country: Number of subjects enrolled	Greece: 12
Country: Number of subjects enrolled	Lithuania: 3
Country: Number of subjects enrolled	Peru: 1

Country: Number of subjects enrolled	Poland: 7
Country: Number of subjects enrolled	Portugal: 6
Worldwide total number of subjects	178
EEA total number of subjects	130

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	123
From 65 to 84 years	54
85 years and over	1

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 183 participants were enrolled. Of these, 178 adults were randomized in a 2:1 ratio and considered for analysis. Additionally, the study included 5 adolescent participants, non-randomized, who received open-label treatment and were not included in the analyses.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Monitor, Data analyst, Carer, Subject, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Ranibizumab

Arm description:

A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.

Arm type	Experimental
Investigational medicinal product name	Ranibizumab
Investigational medicinal product code	RFB002
Other name	Lucentis
Pharmaceutical forms	Injection
Routes of administration	Intravitreal use

Dosage and administration details:

0.5 mg ranibizumab intravitreal injection to the study eye at baseline, and then as needed based on evidence of disease activity

<b>Arm title</b>	Sham control
------------------	--------------

Arm description:

Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Arm type	Placebo
Investigational medicinal product name	Sham
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravitreal use

Dosage and administration details:

Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis. The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.

<b>Number of subjects in period 1</b>	Ranibizumab	Sham control
Started	119	59
Safety set	119	59
Full analysis set	119	59
Completed	112	55
Not completed	7	4
Physician decision	1	2
Consent withdrawn by subject	2	1
Adverse event, non-fatal	1	1
Protocol deviation	1	-
Pregnancy	1	-
Lost to follow-up	1	-

## Baseline characteristics

### Reporting groups

Reporting group title	Ranibizumab
-----------------------	-------------

Reporting group description:

A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.

Reporting group title	Sham control
-----------------------	--------------

Reporting group description:

Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Reporting group values	Ranibizumab	Sham control	Total
Number of subjects	119	59	178
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	82	41	123
From 65-84 years	36	18	54
85 years and over	1	0	1
Age Continuous			
Units: Years			
arithmetic mean	54.6	51.9	
standard deviation	± 15.07	± 17.29	-
Gender, Male/Female			
Units: Participants			
Female	60	30	90
Male	59	29	88

## End points

### End points reporting groups

Reporting group title	Ranibizumab
Reporting group description: A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.	
Reporting group title	Sham control
Reporting group description: Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.	
Subject analysis set title	Sham without Ranibizumab
Subject analysis set type	Full analysis
Subject analysis set description: Participants did not receive ranibizumab at any time during the study.	

### Primary: Change from baseline in best-corrected visual acuity (BCVA) in study eye to Month 2

End point title	Change from baseline in best-corrected visual acuity (BCVA) in study eye to Month 2
End point description: BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.	
End point type	Primary
End point timeframe: Baseline, Month 2	

End point values	Ranibizumab	Sham control		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	57		
Units: letters				
least squares mean (standard error)	9.5 (± 0.95)	-0.4 (± 1.16)		

### Statistical analyses

Statistical analysis title	Change from baseline in BCVA in study eye
Comparison groups	Sham control v Ranibizumab
Number of subjects included in analysis	175
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	Mean difference (net)
Point estimate	9.94

Confidence interval	
level	95 %
sides	2-sided
lower limit	6.97
upper limit	12.91
Variability estimate	Standard error of the mean
Dispersion value	1.502

### Secondary: Change from baseline in BCVA in study eye up to month 2

End point title	Change from baseline in BCVA in study eye up to month 2
End point description: BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.	
End point type	Secondary
End point timeframe: Baseline, Month 1, Month 2	

End point values	Ranibizumab	Sham control		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	57		
Units: letters				
least squares mean (standard error)				
Month 1	7.1 ( $\pm$ 0.75)	0.1 ( $\pm$ 1.08)		
Month 2	9.5 ( $\pm$ 0.91)	-0.4 ( $\pm$ 1.31)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in central subfield thickness (CSFT) in study eye

End point title	Change from baseline in central subfield thickness (CSFT) in study eye
End point description: CSFT was assessed by optical coherence tomography (OCT). A negative change from baseline indicates improvement.	
End point type	Secondary
End point timeframe: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12	



End point values	Ranibizumab	Sham control		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	59		
Units: micrometer (um)				
arithmetic mean (standard deviation)				
Month 1 (n=115,56)	-74.4 (± 81.25)	3.3 (± 89.43)		
Month 2 (n=115,56)	-76.4 (± 108.24)	1.9 (± 119.44)		
Month 3 (n=114,56)	-82.9 (± 114.26)	-59.1 (± 142.37)		
Month 4 (n=114,56)	-83.5 (± 104.71)	-68.4 (± 155.26)		
Month 5 (n=116,55)	-83.8 (± 112.41)	-89.4 (± 130.68)		
Month 6 (n=112,54)	-89.1 (± 109.19)	-85.9 (± 117.54)		
Month 7 (n=114,55)	-83.1 (± 105.97)	-84.5 (± 141.36)		
Month 8 (n=111,55)	-94.7 (± 111.54)	-97.9 (± 118.34)		
Month 9 (n=110,55)	-90 (± 112.44)	-93.5 (± 113.88)		
Month 10 (n=108,53)	-100.5 (± 119.45)	-85.4 (± 136.9)		
Month 11 (n=110,55)	-99.5 (± 112.38)	-82.8 (± 158.78)		
Month 12 (n=109,55)	-102.7 (± 117.27)	-91.7 (± 152.36)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline in central subfield volume (CSFV) in study eye

End point title	Change from baseline in central subfield volume (CSFV) in study eye
-----------------	---

End point description:

CSFV was assessed OCT. A negative change from baseline indicates improvement.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

End point values	Ranibizumab	Sham control		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	59		
Units: microliter (ul)				
arithmetic mean (standard deviation)				
Month 1 (n=115,56)	-0.354 (± 0.4103)	0.012 (± 0.3608)		

Month 2 (n=114,54)	-0.357 (± 0.548)	-0.006 (± 0.5792)		
Month 3 (n=114,56)	-0.369 (± 0.5506)	-0.269 (± 0.6583)		
Month 4 (n=114,56)	-0.371 (± 0.4798)	-0.291 (± 0.7647)		
Month 5 (n=116,55)	-0.392 (± 0.5404)	-0.381 (± 0.575)		
Month 6 (n=112,54)	-0.409 (± 0.5305)	-0.375 (± 0.531)		
Month 7 (n=114,54)	-0.366 (± 0.4905)	-0.374 (± 0.5966)		
Month 8 (n=110,55)	-0.414 (± 0.5021)	-0.411 (± 0.497)		
Month 9 (n=110,55)	-0.404 (± 0.5182)	-0.413 (± 0.5251)		
Month 10 (n=108,53)	-0.437 (± 0.5506)	-0.385 (± 0.5688)		
Month 11 (n=110,55)	-0.448 (± 0.5285)	-0.352 (± 0.7021)		
Month 12 (n=109,55)	-0.441 (± 0.546)	-0.378 (± 0.6704)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with presence of intra-retinal fluid in study eye compared to baseline

End point title	Number of participants with presence of intra-retinal fluid in study eye compared to baseline
End point description: The presence of intra-retinal fluid was assessed by OCT.	
End point type	Secondary
End point timeframe: Baseline, Month 2, Month 6, Month 12	

End point values	Ranibizumab	Sham control		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	59		
Units: Participants				
Month 2, Absent (n=116,56)	97	29		
Month 2, Definite (n=116,56)	19	27		
Month 6, Absent (n=116,54)	100	43		
Month 6, Definite (n=116,54)	16	11		
Month 12, Absent (n=111,55)	95	45		
Month 12, Definite (n=111,55)	16	10		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with presence of subretinal fluid in study eye compared to baseline

End point title	Number of participants with presence of subretinal fluid in study eye compared to baseline
End point description: Presence of subretinal fluid in study eye compared to baseline	
End point type	Secondary
End point timeframe: Baseline, Month 2, Month 6, Month 12	

End point values	Ranibizumab	Sham control		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	59		
Units: Participants				
Month 2, Absent (n=116,56)	72	11		
Month 2, Definite (n=116,56)	44	45		
Month 6, Absent (n=116,54)	77	34		
Month 6, Definite (n=116,54)	39	20		
Month 12, Absent (n=111,55)	78	41		
Month 12, Definite (n=111,55)	33	14		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with presence of active chorioretinal leakage

End point title	Number of participants with presence of active chorioretinal leakage
End point description: The presence of active chorioretinal leakage was assessed by photography imaging, i.e. fluorescein angiography (FA).	
End point type	Secondary
End point timeframe: Baseline, Month 2, Month 6, Month 12	

End point values	Ranibizumab	Sham control		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	59		
Units: Participants				
Month 2, Absent (n=106,50)	37	4		
Month 2, Definite (n=106,50)	69	46		
Month 6, Absent (n=108,45)	64	29		
Month 6, Definite (n=108,45)	44	16		
Month 12, Absent (n=103,47)	81	37		
Month 12, Definite (n=103,47)	22	10		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Average change from baseline in BCVA

End point title	Average change from baseline in BCVA
End point description:	
BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.	
End point type	Secondary
End point timeframe:	
Baseline (BL), Month 1 through Month 6, Month 1 through Month 12	

End point values	Ranibizumab	Sham control		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	59		
Units: letters				
arithmetic mean (standard deviation)				
Average change from BL, month 1 through month 6	9.53 (± 10.467)	4.68 (± 8.786)		
Average change from BL, month 1 through month 12	9.99 (± 11.528)	6.59 (± 10.666)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with ≥ 1, ≥ 5, ≥ 10 and ≥ 15 letters gain or reaching 84 letters

End point title	Number of participants with ≥ 1, ≥ 5, ≥ 10 and ≥ 15 letters gain or reaching 84 letters
End point description:	
VA measurements (number of letters correctly identified) were performed with the patient in a sitting	

position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.

End point type	Secondary
End point timeframe:	
Month 2, Month 6, Month 12	

End point values	Ranibizumab	Sham control		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	59		
Units: Participants				
Month 2, gain of $\geq 15$ letters (n=118,57)	37	7		
Month 2, gain of $\geq 10$ letters (n=118,57)	50	8		
Month 2, gain of $\geq 5$ letters (n=118,57)	83	16		
Month 2, gain of $\geq 1$ letter (118,57)	101	27		
Month 6, gain of $\geq 15$ letters (n=118,54)	53	20		
Month 6, gain of $\geq 10$ letters (n=118,54)	67	24		
Month 6, gain $\geq 5$ letters (n=118,54)	88	34		
Month 6, gain of $\geq 1$ letter (n=118,54)	104	39		
Month 12, gain of $\geq 15$ letters (n=113,55)	55	23		
Month 12, gain of $\geq 10$ letters (n=113,55)	64	28		
Month 12, gain of $\geq 5$ letters (n=113,55)	81	34		
Month 12, gain of $\geq 1$ letter (n=113,55)	100	42		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with $> 1$ , $> 5$ , $> 10$ and $> 15$ letters loss

End point title	Number of participants with $> 1$ , $> 5$ , $> 10$ and $> 15$ letters loss
End point description:	
VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.	
End point type	Secondary
End point timeframe:	
Month 2, Month 6, Month 12	

<b>End point values</b>	Ranibizumab	Sham control		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	59		
Units: Participants				
Month 2, loss of >1 letter (n=118,57)	10	24		
Month 2, loss of >5 letters (n=118,57)	3	12		
Month 2, loss of >10 letters (n=118,57)	1	5		
Month 2, loss of >15 letters (n=118,57)	1	3		
Month 6, loss of >1 letter (n=118,54)	10	9		
Month 6, loss of >5 letters (n=118,54)	7	5		
Month 6, loss of >10 letters (n=118,54)	6	2		
Month 6, loss of >15 letters (n=118,54)	3	2		
Month 12, loss of >1 letter (n=113,55)	9	10		
Month 12, loss of >5 letters (n=113,55)	6	6		
Month 12, loss of >10 letters (n=113,55)	5	4		
Month 12, loss of >15 letters (n=113,55)	3	2		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with requirement for rescue treatment at Month 1

End point title	Number of participants with requirement for rescue treatment at Month 1
End point description: Rescue treatment with laser photocoagulation or periocular treatment could be administered at Month 1 only if the participant had a visual acuity loss of > 5 letters due to disease activity from baseline to Month 1.	
End point type	Secondary
End point timeframe: Month 1	

<b>End point values</b>	Ranibizumab	Sham control		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	58		
Units: Participants	0	1		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with ranibizumab treatments in study eye

End point title	Number of participants with ranibizumab treatments in study eye
End point description: The number of participants, administered study treatments according to treatment frequency, was assessed.	
End point type	Secondary
End point timeframe: Month 12	

End point values	Ranibizumab	Sham control	Sham without Ranibizumab	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	119	52	7	
Units: Participants				
Frequency of injections = 0	0	0	7	
Frequency of injections = 1	12	5	0	
Frequency of injections = 2	12	6	0	
Frequency of injections = 3	19	7	0	
Frequency of injections = 4	13	6	0	
Frequency of injections = 5	9	5	0	
Frequency of injections = 6	11	6	0	
Frequency of injections = 7	2	2	0	
Frequency of injections = 8	8	1	0	
Frequency of injections = 9	5	4	0	
Frequency of injections = 10	7	10	0	
Frequency of injections = 11	6	0	0	
Frequency of injections = 12	15	0	0	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with re-treatments

End point title	Number of participants with re-treatments
End point description: The number of participants administered re-treatments, according to treatment frequency, was assessed. Re-treatment was defined as an administration of study medication following at least one non-missed visit where treatment was not administered in the study eye. Up to Month 12, the maximum number of retreatments was 5.	
End point type	Secondary
End point timeframe: Month 12	

<b>End point values</b>	Ranibizumab	Sham control	Sham without Ranibizumab	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	119	52	7	
Units: Participants				
Frequency of re-treatment = 1	25	21	0	
Frequency of re-treatment = 2	22	10	0	
Frequency of re-treatment = 3	9	4	0	
Frequency of re-treatment = 4	5	2	0	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of primary reasons for decision to treat by Investigator

End point title	Number of primary reasons for decision to treat by Investigator
End point description:	
The total number of primary reasons for decisions to treat was assessed. A single participant could have had multiple primary reasons for treatment.	
End point type	Secondary
End point timeframe:	
Month 12	

<b>End point values</b>	Ranibizumab	Sham control	Sham without Ranibizumab	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	119	52	7	
Units: Number of primary reasons				
Vision impairment	29	9	0	
OCT abnormality	522	306	1	
FA abnormality	21	13	0	
Color fundus photography abnormality	1	0	0	
Clinical abnormality	6	0	0	
Without documentation	1	0	0	

### Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Serious Adverse Events are monitored from date of First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All other adverse events are monitored from First Patient First Treatment until Last Patient Last Visit.

Adverse event reporting additional description:

Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events field "number of deaths resulting from adverse events" all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	18.1

### Reporting groups

Reporting group title	Ranibizumab 0.5 mg
-----------------------	--------------------

Reporting group description:

Ranibizumab 0.5 mg

Reporting group title	Sham without Ranibizumab 0.5 mg
-----------------------	---------------------------------

Reporting group description:

Sham without Ranibizumab 0.5 mg

Reporting group title	Sham with Ranibizumab 0.5 mg
-----------------------	------------------------------

Reporting group description:

Sham with Ranibizumab 0.5 mg

Serious adverse events	Ranibizumab 0.5 mg	Sham without Ranibizumab 0.5 mg	Sham with Ranibizumab 0.5 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 119 (7.56%)	0 / 7 (0.00%)	4 / 52 (7.69%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Hepatocellular carcinoma			
subjects affected / exposed	0 / 119 (0.00%)	0 / 7 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intraductal papilloma of breast			
subjects affected / exposed	1 / 119 (0.84%)	0 / 7 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Invasive lobular breast carcinoma subjects affected / exposed	1 / 119 (0.84%)	0 / 7 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pituitary tumour benign subjects affected / exposed	1 / 119 (0.84%)	0 / 7 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders Peripheral artery stenosis subjects affected / exposed	1 / 119 (0.84%)	0 / 7 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders Atrial fibrillation subjects affected / exposed	1 / 119 (0.84%)	0 / 7 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders Parkinsonism subjects affected / exposed	1 / 119 (0.84%)	0 / 7 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions Pyrexia subjects affected / exposed	0 / 119 (0.00%)	0 / 7 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders Retinal detachment (Fellow untreated eye) subjects affected / exposed	1 / 119 (0.84%)	0 / 7 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Abdominal pain upper			
subjects affected / exposed	1 / 119 (0.84%)	0 / 7 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 119 (0.00%)	0 / 7 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	1 / 119 (0.84%)	0 / 7 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 119 (0.00%)	0 / 7 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Oliguria			
subjects affected / exposed	0 / 119 (0.00%)	0 / 7 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Rheumatic disorder			
subjects affected / exposed	0 / 119 (0.00%)	0 / 7 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Urosepsis			
subjects affected / exposed	0 / 119 (0.00%)	0 / 7 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Ranibizumab 0.5 mg	Sham without Ranibizumab 0.5 mg	Sham with Ranibizumab 0.5 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	42 / 119 (35.29%)	4 / 7 (57.14%)	19 / 52 (36.54%)
Vascular disorders			
Hypertension			
subjects affected / exposed	5 / 119 (4.20%)	1 / 7 (14.29%)	1 / 52 (1.92%)
occurrences (all)	5	1	1
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 119 (0.84%)	1 / 7 (14.29%)	3 / 52 (5.77%)
occurrences (all)	1	1	3
Eye disorders			
Choroidal neovascularisation (Study eye)			
subjects affected / exposed	3 / 119 (2.52%)	1 / 7 (14.29%)	0 / 52 (0.00%)
occurrences (all)	3	1	0
Conjunctival haemorrhage (Study eye)			
subjects affected / exposed	7 / 119 (5.88%)	0 / 7 (0.00%)	6 / 52 (11.54%)
occurrences (all)	8	0	7
Eye inflammation (Study eye)			
subjects affected / exposed	0 / 119 (0.00%)	1 / 7 (14.29%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Foreign body sensation in eyes (Study eye)			
subjects affected / exposed	1 / 119 (0.84%)	1 / 7 (14.29%)	1 / 52 (1.92%)
occurrences (all)	1	1	1
Macular oedema (Study eye)			
subjects affected / exposed	0 / 119 (0.00%)	1 / 7 (14.29%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Ocular hyperaemia (Study eye)			
subjects affected / exposed	1 / 119 (0.84%)	1 / 7 (14.29%)	1 / 52 (1.92%)
occurrences (all)	1	1	1
Photopsia (Study eye)			
subjects affected / exposed	1 / 119 (0.84%)	1 / 7 (14.29%)	0 / 52 (0.00%)
occurrences (all)	1	1	0

Visual acuity reduced (Study eye) subjects affected / exposed occurrences (all)	3 / 119 (2.52%) 3	1 / 7 (14.29%) 1	1 / 52 (1.92%) 2
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	6 / 119 (5.04%) 6	1 / 7 (14.29%) 1	0 / 52 (0.00%) 0
Infections and infestations Conjunctivitis (Study eye) subjects affected / exposed occurrences (all)	2 / 119 (1.68%) 2	0 / 7 (0.00%) 0	3 / 52 (5.77%) 3
Influenza subjects affected / exposed occurrences (all)	9 / 119 (7.56%) 9	0 / 7 (0.00%) 0	0 / 52 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	14 / 119 (11.76%) 19	1 / 7 (14.29%) 1	9 / 52 (17.31%) 12
Pneumonia subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 1	1 / 7 (14.29%) 1	0 / 52 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	2 / 119 (1.68%) 2	0 / 7 (0.00%) 0	3 / 52 (5.77%) 4

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
04 May 2014	Amendment 1 (04-May-2014) was a substantial amendment and was issued 8 months after study start (when 28 patients were enrolled) and introduced the following changes: protocol-specified retreatment criteria were aligned with current medical practice for the management of patients with visual impairment due to CNV, specifically the inclusion of anatomic parameters, in addition to BCVA; eligibility criteria were revised to exclude two additional CNV conditions that are considered sub-categories of nAMD: 1) PCV and 2) RAP lesions in patients $\geq 50$ years of age. The classification of these two CNV conditions as nAMD was not explicitly mentioned in the original protocol, which led to inclusion of some patients with these conditions; and two optional tests, visual field and electroretinography, were removed based on expert feedback.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported